용한점집 금휘궁 갤러리

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Miglitol is an oral anti-diabetic medication belonging to the class of drugs known as alpha-glucosidase inhibitors. Primarily used in the management of type 2 diabetes mellitus, it functions by delaying the digestion and absorption of carbohydrates from the small intestine, thereby moderating postprandial (after-meal) blood glucose spikes. This report details its pharmacology, clinical use, efficacy, safety profile, and position in diabetes care.

Pharmacology and Mechanism of Action
Miglitol is a pseudotetrasaccharide derived from Streptomyces bacteria. Its chemical structure is similar to that of the monosaccharide glucose. Unlike sulfonylureas or metformin, miglitol does not directly affect insulin secretion or improve insulin sensitivity. Instead, it acts locally within the gastrointestinal tract.

Its primary mechanism involves the competitive and reversible inhibition of alpha-glucosidase enzymes located on the brush border of the small intestinal epithelium. These enzymes, such as sucrase, maltase, glucoamylase, and isomaltase, are responsible for breaking down complex carbohydrates (like starch, sucrose, and maltose) into monosaccharides (glucose, fructose) that can be absorbed into the bloodstream. By inhibiting these enzymes, miglitol slows the conversion of oligosaccharides and disaccharides into glucose. This results in a delayed and Revisión Basada en Evidencia more gradual rise in blood glucose levels following a meal, smoothing out postprandial hyperglycemia—a key contributor to overall glycemic control as measured by HbA1c.

Crucially, miglitol is minimally absorbed systemically (less than 2% of an oral dose). It exerts its action locally in the gut and is excreted unchanged in the feces. This limited absorption contributes to its specific side effect profile.

Indications and Clinical Use
Miglitol is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is most effective in controlling postprandial glucose excursions. It can be used as monotherapy or in combination with other oral anti-diabetic agents, such as metformin or sulfonylureas, when monotherapy does not provide adequate control. It is not indicated for type 1 diabetes or for the treatment of diabetic ketoacidosis.

The typical starting dose is 25 mg taken three times daily at the beginning (with the first bite) of each main meal. The dose can be gradually increased to a maintenance dose of 50 mg three times daily, and a maximum dose of 100 mg three times daily, based on tolerability and effectiveness. Administration must be concurrent with the first bite of the meal to ensure the drug is present when carbohydrates enter the small intestine.

Efficacy
Clinical trials have demonstrated that miglitol effectively lowers postprandial blood glucose levels and reduces HbA1c by approximately 0.5% to 1.0% on average. Its effect is most pronounced on postprandial glucose, making it a particularly useful agent for individuals whose HbA1c is driven predominantly by high after-meal glucose values. It does not cause hypoglycemia when used as monotherapy. Furthermore, some studies suggest it may have a modest beneficial effect on postprandial triglycerides.

Safety Profile and Adverse Effects
The most common adverse effects of miglitol are gastrointestinal, directly resulting from its mechanism of action. Undigested carbohydrates proceed to the large intestine, where they are fermented by colonic bacteria, producing gas and drawing fluid into the colon. This leads to symptoms such as flatulence, diarrhea, abdominal distention, and abdominal pain. These effects are dose-dependent and often diminish in frequency and intensity over several weeks as the body adapts. Starting with a low dose and gradually titrating upward can improve tolerability.

Because miglitol delays carbohydrate absorption, it can potentiate the hypoglycemic effects of insulin and insulin secretagogues (like sulfonylureas). If hypoglycemia occurs while a patient is on combination therapy, it must be treated with oral glucose (dextrose) or glucagon injection, not sucrose (table sugar), as miglitol will inhibit the breakdown of sucrose into glucose and fructose.

Contraindications include hypersensitivity to miglitol, diabetic ketoacidosis, inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or chronic intestinal diseases associated with marked disorders of digestion or absorption. It is also contraindicated in patients with conditions that may deteriorate due to increased gas formation in the intestine (e.g., significant hernias).

Comparison and Place in Therapy
Within the alpha-glucosidase inhibitor class, miglitol is often compared to acarbose. Both share a similar mechanism and GI side effect profile. A key difference is in absorption: acarbose is minimally absorbed but has some systemic activity, while miglitol is almost entirely unabsorbed. Miglitol is also a more potent inhibitor of sucrase. In practice, their efficacy and tolerability are very similar.

In the broader landscape of type 2 diabetes management, miglitol occupies a niche role. First-line therapy typically begins with metformin and lifestyle modification. Miglitol may be considered for patients who need additional postprandial control, especially if they are not candidates for other agents or wish to avoid systemic effects and weight gain (miglitol is weight-neutral). Its use has declined in many regions with the advent of newer classes like DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors, which often offer better efficacy and fewer GI side effects. However, miglitol remains a cost-effective option in certain healthcare settings.

Conclusion
Miglitol is a well-established alpha-glucosidase inhibitor that provides a mechanistic approach to managing postprandial hyperglycemia in type 2 diabetes. Its localized action in the gut, weight-neutral profile, and low risk of hypoglycemia (as monotherapy) are distinct advantages. However, its utility is limited by a high incidence of gastrointestinal side effects and the need for frequent dosing with meals. While newer therapeutic classes have become more prominent, miglitol retains a role as an adjunctive therapy, particularly when postprandial glucose is a primary concern and its side effect profile is manageable for the individual patient. As with all anti-diabetic treatments, its use must be individualized within the context of comprehensive diabetes care.